Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
US9180186B2 · kind B2 · utility
5Cited by
20References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2011 |
| Grant date | Nov 10, 2015 |
| Priority date | — |
| Expiry date | Jun 1, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.